Novo Nordisk presents Fiasp and semaglutide data at EASD

Danish diabetes care giant Novo Nordisk (NOV: N) has released new data showing that its Fiasp (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (the company’s NovoRapid brand), in new study findings.

The findings were presented today at the 53rd European Association for the Study of Diabetes (EASD) Annual Meeting in Portugal, and showed that Fiasp maintained the significant improvement in overall blood sugar control that was seen in a shorter-term (26 weeks) study period. The results also reconfirmed the safety profile of Fiasp, showing comparable overall numbers of severe or blood-sugar confirmed hypoglycemia (low blood sugar levels).

"These results provide reassurance of the meaningful long-term benefits of Fiasp versus conventional insulin aspart," said Professor Chantal Mathieu, study investigator, chair of Endocrinology and professor of Medicine at Katholieke Universiteit Leuven, Belgium. "Accordingly, for people with diabetes who struggle to control their post-meal sugar levels, Fiasp might offer a better option to meet their needs," he noted.